FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W63425872> ?p ?o ?g. }

• W63425872 endingPage "2082" @default.
• W63425872 startingPage "2071" @default.
• W63425872 abstract "Adherence to evidence-based cardiovascular (CV) medications after an acute myocardial infarction (MI) is low after the first 6 months. The use of fixed-dose combinations (FDC) has been shown to improve treatment adherence and risk factor control. However, no previous randomized trial has analyzed the impact of a polypill strategy on adherence in post-MI patients. The cross-sectional FOCUS (Fixed-Dose Combination Drug for Secondary Cardiovascular Prevention) study (Phase 1) aimed to elucidate factors that interfere with appropriate adherence to CV medications for secondary prevention after an acute MI. Additionally, 695 patients from Phase 1 were randomized into a controlled trial (Phase 2) to test the effect of a polypill (containing aspirin 100 mg, simvastatin 40 mg, and ramipril 2.5, 5, or 10 mg) compared with the 3 drugs given separately on adherence, blood pressure, and low-density lipoprotein cholesterol, as well as safety and tolerability over a period of 9 months of follow-up. In Phase 1, a 5-country cohort of 2,118 patients was analyzed. Patients were randomized to either the polypill or 3 drugs separately for Phase 2. Primary endpoint was adherence to the treatment measured at the final visit by the self-reported Morisky-Green questionnaire (MAQ) and pill count (patients had to meet both criteria for adherence at the in-person visit to be considered adherent). In Phase 1, overall CV medication adherence, defined as an MAQ score of 20, was 45.5%. In a multivariable regression model, the risk of being nonadherent (MAQ <20) was associated with younger age, depression, being on a complex medication regimen, poorer health insurance coverage, and a lower level of social support, with consistent findings across countries. In Phase 2, the polypill group showed improved adherence compared with the group receiving separate medications after 9 months of follow-up: 50.8% versus 41% (p = 0.019; intention-to-treat population) and 65.7% versus 55.7% (p = 0.012; per protocol population) when using the primary endpoint, attending the final visit with MAQ = 20 and high pill count (80% to 110%) combined, to assess adherence. Adherence also was higher in the FDC group when measured by MAQ alone (68% vs. 59%, p = 0.049). No treatment difference was found at follow-up in mean systolic blood pressure (129.6 mm Hg vs. 128.6 mm Hg), mean low-density lipoprotein cholesterol levels (89.9 mg/dl vs. 91.7 mg/dl), serious adverse events (23 vs. 21), or death (1, 0.3% in each group). For secondary prevention following acute MI, younger age, depression, and a complex drug treatment plan are associated with lower medication adherence. Meanwhile, adherence is increased in patients with higher insurance coverage levels and social support. Compared with the 3 drugs given separately, the use of a polypill strategy met the primary endpoint for adherence for secondary prevention following an acute MI. (Fixed Dose Combination Drug [Polypill] for Secondary Cardiovascular Prevention [FOCUS]; NCT01321255)" @default.
• W63425872 created "2016-06-24" @default.
• W63425872 creator A5004569307 @default.
• W63425872 creator A5005595943 @default.
• W63425872 creator A5009159473 @default.
• W63425872 creator A5010195705 @default.
• W63425872 creator A5010258190 @default.
• W63425872 creator A5018220482 @default.
• W63425872 creator A5023436129 @default.
• W63425872 creator A5027203824 @default.
• W63425872 creator A5033778167 @default.
• W63425872 creator A5033939043 @default.
• W63425872 creator A5034537174 @default.
• W63425872 creator A5037254764 @default.
• W63425872 creator A5037397909 @default.
• W63425872 creator A5042204674 @default.
• W63425872 creator A5043621364 @default.
• W63425872 creator A5048103623 @default.
• W63425872 creator A5048427107 @default.
• W63425872 creator A5052006329 @default.
• W63425872 creator A5063852420 @default.
• W63425872 creator A5069530076 @default.
• W63425872 creator A5070148218 @default.
• W63425872 creator A5071830292 @default.
• W63425872 creator A5074727212 @default.
• W63425872 creator A5077938436 @default.
• W63425872 date "2014-11-01" @default.
• W63425872 modified "2023-10-18" @default.
• W63425872 title "A Polypill Strategy to Improve Adherence" @default.
• W63425872 cites W1227667404 @default.
• W63425872 cites W161660362 @default.
• W63425872 cites W1985949001 @default.
• W63425872 cites W1992883745 @default.
• W63425872 cites W2031756259 @default.
• W63425872 cites W2034159424 @default.
• W63425872 cites W2037450761 @default.
• W63425872 cites W2042394770 @default.
• W63425872 cites W2056208826 @default.
• W63425872 cites W2063609516 @default.
• W63425872 cites W2067694868 @default.
• W63425872 cites W2080772071 @default.
• W63425872 cites W2093764440 @default.
• W63425872 cites W2097285811 @default.
• W63425872 cites W2098194481 @default.
• W63425872 cites W2101621119 @default.
• W63425872 cites W2104269881 @default.
• W63425872 cites W2108380836 @default.
• W63425872 cites W2123277906 @default.
• W63425872 cites W2150278133 @default.
• W63425872 doi "https://doi.org/10.1016/j.jacc.2014.08.021" @default.
• W63425872 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25193393" @default.
• W63425872 hasPublicationYear "2014" @default.
• W63425872 type Work @default.
• W63425872 sameAs 63425872 @default.
• W63425872 citedByCount "268" @default.
• W63425872 countsByYear W634258722013 @default.
• W63425872 countsByYear W634258722014 @default.
• W63425872 countsByYear W634258722015 @default.
• W63425872 countsByYear W634258722016 @default.
• W63425872 countsByYear W634258722017 @default.
• W63425872 countsByYear W634258722018 @default.
• W63425872 countsByYear W634258722019 @default.
• W63425872 countsByYear W634258722020 @default.
• W63425872 countsByYear W634258722021 @default.
• W63425872 countsByYear W634258722022 @default.
• W63425872 countsByYear W634258722023 @default.
• W63425872 crossrefType "journal-article" @default.
• W63425872 hasAuthorship W63425872A5004569307 @default.
• W63425872 hasAuthorship W63425872A5005595943 @default.
• W63425872 hasAuthorship W63425872A5009159473 @default.
• W63425872 hasAuthorship W63425872A5010195705 @default.
• W63425872 hasAuthorship W63425872A5010258190 @default.
• W63425872 hasAuthorship W63425872A5018220482 @default.
• W63425872 hasAuthorship W63425872A5023436129 @default.
• W63425872 hasAuthorship W63425872A5027203824 @default.
• W63425872 hasAuthorship W63425872A5033778167 @default.
• W63425872 hasAuthorship W63425872A5033939043 @default.
• W63425872 hasAuthorship W63425872A5034537174 @default.
• W63425872 hasAuthorship W63425872A5037254764 @default.
• W63425872 hasAuthorship W63425872A5037397909 @default.
• W63425872 hasAuthorship W63425872A5042204674 @default.
• W63425872 hasAuthorship W63425872A5043621364 @default.
• W63425872 hasAuthorship W63425872A5048103623 @default.
• W63425872 hasAuthorship W63425872A5048427107 @default.
• W63425872 hasAuthorship W63425872A5052006329 @default.
• W63425872 hasAuthorship W63425872A5063852420 @default.
• W63425872 hasAuthorship W63425872A5069530076 @default.
• W63425872 hasAuthorship W63425872A5070148218 @default.
• W63425872 hasAuthorship W63425872A5071830292 @default.
• W63425872 hasAuthorship W63425872A5074727212 @default.
• W63425872 hasAuthorship W63425872A5077938436 @default.
• W63425872 hasBestOaLocation W634258721 @default.
• W63425872 hasConcept C126322002 @default.
• W63425872 hasConcept C168563851 @default.
• W63425872 hasConcept C197934379 @default.
• W63425872 hasConcept C203092338 @default.
• W63425872 hasConcept C2776329913 @default.
• W63425872 hasConcept C2776623344 @default.

• next